Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237672 | 0.80 | KMT2A (0.41) | KMT2AHTTMAPTMEN1NPSR1 | |
| SCHEMBL1236640 | 0.74 | PIK3CG (0.48) | — | |
| SCHEMBL1237331 | 0.69 | CA12 (0.39) | KMT2AHTTMAPTMEN1NPSR1 | |
| SCHEMBL9071117 | 0.65 | MAPT (0.53) | KMT2AHTTMAPTMEN1NPSR1 | |
| SCHEMBL1237271 | 0.65 | MAPT (0.39) | KMT2AHTTMAPTMEN1NPSR1 | |
| SCHEMBL998820 | 0.61 | HTT (0.51) | KMT2AHTTMAPTMEN1NPSR1 | |
| SCHEMBL31436932 | 0.60 | ALDH1A1 (0.53) | KMT2AHTTMAPTMEN1NPSR1 | |
| SCHEMBL971984 | 0.60 | HTT (0.49) | KMT2AHTTMAPTMEN1NPSR1 | |
| SCHEMBL30267722 | 0.59 | MAPT (0.57) | KMT2AMAPTL3MBTL1ALDH1A1TSHR | |
| SCHEMBL31436856 | 0.59 | KMT2A (0.48) | KMT2AMEN1NPSR1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399497-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2013-03-19 | — | — | US | disclosed |
| US-20110086843-A1 | Thiazole Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-7879888-B2 | N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-20080221180-A1 | Thiazole Derivatives and Use Thereof | LABORATORIES SERONO SA (CH) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221180-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | KMT2A 4737/4885HTT 1558/4885MAPT 1418/4885 |
| US-20110086843-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | KMT2A 4737/4885HTT 1558/4885MAPT 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.